Evidence map›Paper›PMID 32437779›Full record

ArticleToxicology2020

Dual mechanisms suppress meloxicam bioactivation relative to sudoxicam.

Dustyn A Barnette, Mary A Schleiff, Laura R Osborn, Noah Flynn, Matthew Matlock, S Joshua Swamidass, Grover P Miller

Open access · greenAbstract read
In one paragraph

Article in Toxicology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Dustyn A BarnetteDepartment of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, 4301 W Markham St, Little Rock, AR, 72205, United States.
Mary A SchleiffDepartment of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, 4301 W Markham St, Little Rock, AR, 72205, United States.
Laura R OsbornDepartment of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, 4301 W Markham St, Little Rock, AR, 72205, United States.
Noah FlynnDepartment of Pathology and Immunology, 660 S Euclid Ave, Washington University, St. Louis, MO, 63130, United States.
Matthew MatlockDepartment of Pathology and Immunology, 660 S Euclid Ave, Washington University, St. Louis, MO, 63130, United States.
S Joshua SwamidassDepartment of Pathology and Immunology, 660 S Euclid Ave, Washington University, St. Louis, MO, 63130, United States.
Grover P MillerDepartment of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, 4301 W Markham St, Little Rock, AR, 72205, United States. Electronic address: millergroverp@uams.edu.
University of Arkansas for Medical Sciences · USWashington University in St. Louis · US

Funding

HIGH PERFORMANCE BIOMEDICAL IMAGING COMPUTER RESOURCESS10RR022984 · NCRR · WASHINGTON UNIVERSITY · PI PRIOR, FRED WILLIAM · 2009 to 2009
$1.9M
DATA AND TOOLS FOR MODELING METABOLISM AND REACTIVITYR01LM012222 · NLM · WASHINGTON UNIVERSITY · PI MILLER, GROVER P, SWAMIDASS, SANJAY JOSHUA · 2016 to 2019
$1.5M
Systems Pharmacology and Toxicology Training ProgramT32GM106999 · NIGMS · UNIV OF ARKANSAS FOR MED SCIS · PI PRATHER, PAUL L · 2013 to 2022
$1.4M
Computationally modeling the impact of ontogeny on drug metabolic fateR01LM012482 · NLM · UNIV OF ARKANSAS FOR MED SCIS · PI MILLER, GROVER P, SWAMIDASS, SANJAY JOSHUA · 2016 to 2019
$1.3M
GPU COMPUTING RESOURCE TO ENABLE INNOVATION IN IMAGING AND NETWORK BIOLOGYS10OD018091 · OD · WASHINGTON UNIVERSITY · PI PAPPU, ROHIT V, PRIOR, FRED WILLIAM · 2014 to 2014
$598k
NCRR NIH HHS S10 RR022984NIGMS NIH HHS T32 GM106999NIH HHS S10 OD018091NLM NIH HHS R01 LM012222NLM NIH HHS R01 LM012482
6 · The paper itself

Abstract

Thiazoles are biologically active aromatic heterocyclic rings occurring frequently in natural products and drugs. These molecules undergo typically harmless elimination; however, a hepatotoxic response can occur due to multistep bioactivation of the thiazole to generate a reactive thioamide. A basis for those differences in outcomes remains unknown. A textbook example is the high hepatotoxicity observed for sudoxicam in contrast to the relative safe use and marketability of meloxicam, which differs in structure from sudoxicam by the addition of a single methyl group. Both drugs undergo bioactivation, but meloxicam exhibits an additional detoxification pathway due to hydroxylation of the methyl group. We hypothesized that thiazole bioactivation efficiency is similar between sudoxicam and meloxicam due to the methyl group being a weak electron donator, and thus, the relevance of bioactivation depends on the competing detoxification pathway. For a rapid analysis, we modeled epoxidation of sudoxicam derivatives to investigate the impact of substituents on thiazole bioactivation. As expected, electron donating groups increased the likelihood for epoxidation with a minimal effect for the methyl group, but model predictions did not extrapolate well among all types of substituents. Through analytical methods, we measured steady-state kinetics for metabolic bioactivation of sudoxicam and meloxicam by human liver microsomes. Sudoxicam bioactivation was 6-fold more efficient than that for meloxicam, yet meloxicam showed a 6-fold higher efficiency of detoxification than bioactivation. Overall, sudoxicam bioactivation was 15-fold more likely than meloxicam considering all metabolic clearance pathways. Kinetic differences likely arise from different enzymes catalyzing respective metabolic pathways based on phenotyping studies. Rather than simply providing an alternative detoxification pathway, the meloxicam methyl group suppressed the bioactivation reaction. These findings indicate the impact of thiazole substituents on bioactivation is more complex than previously thought and likely contributes to the unpredictability of their toxic potential.

Indexed as

Activation, MetabolicBiotransformationChemical and Drug Induced Liver InjuryElectronsEpoxy CompoundsHumansHydroxylationIn Vitro TechniquesKineticsMeloxicamMetabolic Networks and PathwaysMicrosomes, LiverThiazinesThiazolesEpoxy CompoundsMeloxicamsudoxicamThiazinesThiazolesBioactivationKineticsLiver toxicityMeloxicamSudoxicamThiazole

Identifiers

PMID32437779
PMCPMC8716319
OpenAlexW3023457492

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.